Evidence map›Paper›PMID 40475781›Full record

ArticleFrontiers in immunology2025

Yuya Hirasawa, Junya Isobe, Masahiro Hosonuma, Toshiaki Tsurui, Yuta Baba, Eiji Funayama, Kohei Tajima, Masakazu Murayama, Yoichiro Narikawa, Hitoshi Toyoda and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Yuya Hirasawa *Division of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Junya Isobe *Department of Hospital Pharmaceutics, School of Pharmacy, Showa Medical University, Tokyo, Japan.
Masahiro HosonumaDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Toshiaki TsuruiDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Yuta BabaDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Eiji FunayamaDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Kohei TajimaDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Masakazu MurayamaDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Yoichiro NarikawaDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Hitoshi ToyodaDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Midori ShidaDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Aya SasakiDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Yuuki MaruyamaDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Yasunobu AmariDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Emiko MuraDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Risako SuzukiDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Nana IriguchiDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Tomoyuki IshiguroDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Ryotaro OhkumaDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Masahiro ShimokawaDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Hirotsugu AriizumiDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Yutaro KubotaDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Atsushi HoriikeDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Takehiko SambeClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Naoki UchidaDivision of Clinical Pharmacology, Department of Pharmacology, Showa Medical University School of Medicine, Tokyo, Japan.
Satoshi WadaDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Shinichi KobayashiClinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Yuji KiuchiDepartment of Pharmacology, Showa Medical University Graduate School of Medicine, Tokyo, Japan.
Atsuo KuramasuDepartment of Clinical Immuno-Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, Tokyo, Japan.
Kiyoshi YoshimuraDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.
Takuya TsunodaDivision of Medical Oncology, Department of Medicine, Showa Medical University School of Medicine, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The rapid increase in the number of elderly patients with cancer necessitates treatment strategies based on the effects of aging because of drastic side effects of cytotoxic anticancer agents. Immune checkpoint inhibitors (ICIs) are relatively less toxic and can be easily administered to vulnerable and aged patients suffering from cancer. The diversity of gut microbiota and specific bacteria affects the efficacy and safety of ICIs. Therefore, this study aimed to assess the effect of aging on gut microbiota that play crucial roles in determining antitumor efficacy of drugs. Methods: Stool samples were collected from 36 aged patients pathologically diagnosed with solid tumors before the start of drug therapy, and gut microbial composition was analyzed using next generation sequencing. The association between gut microbiota and efficacy and safety of ICIs was analyzed. Results: The abundance of Conclusions: These gut microbiota changes with aging, and its characteristics are important parameters that also affect the efficacy of ICIs.

Indexed as

AgingGastrointestinal MicrobiomeImmune Checkpoint InhibitorsNeoplasmsStreptococcusVeillonellaAgedAged, 80 and overFecesFemaleHumansMaleMiddle AgedTreatment OutcomeImmune Checkpoint Inhibitorsaginggut microbiotaimmune checkpoint inhibitorStreptococcusVeillonella

Identifiers

PMID40475781
PMCPMC12138196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.